Shaare Zedek Medical Center
Jerusalem's community-facing academic hospital, home of ESMO-MCBS architect Nathan Cherny and leading BRCA population screening research.
Founded in 1902, Shaare Zedek Medical Center is one of Jerusalem's two large academic hospitals. Nathan Cherny, who directs its cancer pain and palliative medicine service, chairs the working group behind the ESMO Magnitude of Clinical Benefit Scale used to grade the value of cancer treatments, and Ephrat Levy-Lahad's Medical Genetics Institute has led studies showing the feasibility of population-based BRCA1/2 screening in Ashkenazi Jewish women. The hospital's oncology and haematology institutes provide comprehensive treatment, and the centre has a strong tradition in supportive and palliative care, medical ethics and access to medicines research.
- Palliative medicine and ESMO-MCBS
- Medical genetics and BRCA population screening
- Oncology and haematology institutes
Pages like this
not linked directly; found by shared links- IdeaOncology teams order germline tests; tele-genetic counsellors handle the results
Shares Inherited risk is mostly unidentified, Germline (hereditary) testing, Ovarian cancer, HR-positive / HER2-negative breast cancer.
- IdeaPopulation germline screening for hereditary cancer genes with cascade testing
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.
- IdeaGo back to families of women who died of ovarian cancer and offer BRCA testing
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.
- InstitutionInstituto Português de Oncologia do Porto Francisco Gentil
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Ovarian cancer.
- IdeaTreat wasting like sepsis: a trigger, a bundle, an audit
Shares Nathan Cherny, Pain relief and palliative care are unavailable to most, Geriatric assessment.
- InstitutionUniversity of Malaya Medical Centre
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- IdeaUse a polygenic risk score to set when screening starts
Shares Inherited risk is mostly unidentified, Germline (hereditary) testing, HR-positive / HER2-negative breast cancer, Colorectal cancer.
- IdeaAutomatic germline testing for every cancer type where it changes care
Shares Inherited risk is mostly unidentified, Germline (hereditary) testing, Ovarian cancer, Colorectal cancer.